Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bcr-2020-241047 http://scihub22266oqcxt.onion/10.1136/bcr-2020-241047 33622757!7907860!33622757     free     free     free       BMJ+Case+Rep 2021 ; 14 (2): ä Nephropedia Template TP {{tp|p=33622757|t=2021. COVID-19 cardiac injury and the use of colchicine |pdf=|usr=}}{{33622757}} gab.com Text COVID-19 cardiac injury and the use of colchicine JO: BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33622757 #FOAvip We report a case of cardiac injury in a 46-year-old man affected by COVID-19. The patient presented with shortness of breath and fever. ECG revealed sinus tachycardia with ventricular extrasystoles and T-wave inversion in anterior leads. Troponin T and N-terminal pro B-type natriuretic peptide were elevated. Transthoracic echocardiography showed severely reduced systolic function with an estimated left ventricle ejection fraction of 30%. A nasopharingeal swab was positive for SARS-CoV-2. On day 6, 11 days after onset of symptoms, the patient deteriorated clinically with new chest pain and type 1 respiratory failure. Treatment with colchicine 0.5 mg 8-hourly resulted in rapid clinical resolution. This case report highlights how cardiac injury can dominate the clinical picture in COVID-19 infection. The role of colchicine therapy should be further studied to determine its usefulness in reducing myocardial and possibly lung parenchymal inflammatory responses. Twit Text FOAVip COVID-19 cardiac injury and the use of colchicine ????BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33622757 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33622757 #FOAvip English Wikipedia <ref>{{Cite pmid|33622757}}</ref> COVID-19 cardiac injury and the use of colchicine #MMPMID33622757 Anton-Vazquez V; Byrne L; Anderson L; Hamzah L BMJ Case Rep 2021[Feb]; 14 (2): ä PMID33622757show ga We report a case of cardiac injury in a 46-year-old man affected by COVID-19. The patient presented with shortness of breath and fever. ECG revealed sinus tachycardia with ventricular extrasystoles and T-wave inversion in anterior leads. Troponin T and N-terminal pro B-type natriuretic peptide were elevated. Transthoracic echocardiography showed severely reduced systolic function with an estimated left ventricle ejection fraction of 30%. A nasopharingeal swab was positive for SARS-CoV-2. On day 6, 11 days after onset of symptoms, the patient deteriorated clinically with new chest pain and type 1 respiratory failure. Treatment with colchicine 0.5 mg 8-hourly resulted in rapid clinical resolution. This case report highlights how cardiac injury can dominate the clinical picture in COVID-19 infection. The role of colchicine therapy should be further studied to determine its usefulness in reducing myocardial and possibly lung parenchymal inflammatory responses. |*COVID-19 Drug Treatment[MESH] |COVID-19/*complications[MESH] |Chest Pain/virology[MESH] |Colchicine/*therapeutic use[MESH] |Echocardiography[MESH] |Heart Diseases/*drug therapy/*virology[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Myocardium/pathology[MESH] |Natriuretic Peptide, Brain/blood[MESH] |Peptide Fragments/blood[MESH] |Systole[MESH]COVID-19 cardiac injury and the use of colchicine (epmc).pdf DeepDyve Pubget Overpricing